IPSEN |
Market Closed -
Other stock markets
|
After market 03:19:17 pm | |||
| 108.4 EUR | +1.98% |
|
108.2 | -0.23% |
| Apr. 15 | Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights | CF |
| Apr. 02 | Ipsen: worldwide licensing agreement with Sutro Biopharma | CF |
Business Summary
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Number of employees: 5,325
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Oncology
75.2
%
| 2,380 | 78.7 % | 2,351 | 75.2 % | -1.19% |
Neurosciences
21.1
%
| 604 | 20.0 % | 659 | 21.1 % | +9.08% |
Rare Diseases
3.7
%
| 41 | 1.4 % | 117 | 3.7 % | +184.43% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Europe
40.2
%
| 1,237 | 40.9 % | 1,257 | 40.2 % | +1.56% |
North America
33.3
%
| 1,032 | 34.1 % | 1,042 | 33.3 % | +0.94% |
Rest of the World
26.5
%
| 756 | 25.0 % | 829 | 26.5 % | +9.73% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 54 | 14-11-02 | |
| Chairman | 66 | 10-11-21 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 23-05-04 |
| Chief Tech/Sci/R&D Officer | 57 | 23-09-21 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 17-12-31 |
Craig Marks
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 22-02-28 | |
| Corporate Officer/Principal | - | 20-09-30 | |
| Corporate Officer/Principal | 50 | 21-10-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Chairman | 66 | 10-11-21 | |
Henri Beaufour
BRD | Director/Board Member | 59 | 05-08-29 |
Antoine Flochel
BRD | Director/Board Member | 59 | 05-08-29 |
Carol Xueref
BRD | Director/Board Member | 67 | 12-05-31 |
Piet Wigerinck
BRD | Director/Board Member | 58 | 18-04-30 |
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director/Board Member | 44 | 20-11-05 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 83,814,526 | 34,798,107 ( 41.52 %) | 1,116,316 ( 1.332 %) | 41.52 % |
Holdings
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Socapharma SAS
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
106.3
EUR
Average target price
124.6
EUR
Spread / Average Target
+17.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.28% | 9.36B | |
| +27.40% | 672B | |
| +24.05% | 550B | |
| -7.11% | 351B | |
| +15.18% | 317B | |
| +6.46% | 292B | |
| +2.62% | 211B | |
| -0.19% | 203B | |
| -11.52% | 144B | |
| -8.46% | 141B |
- Stock Market
- Equities
- IPN Stock
- Company Ipsen
